ENSC — Ensysce Biosciences, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1716947 ·
Last close
$0.31
Market Cap
$4.52M
52W High
$0.77
52W Low
$0.23
ADV30
3,608,148
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -3,562,230 | -3,556,415 | 2,167,803 | 745,482 | 2,836,815 |
| Dec 2025 | 0 | — | -2,781,825 | -2,767,648 | 7,452,479 | 4,310,354 | 4,567,729 |
| Sep 2025 | 0 | — | -3,741,095 | -3,729,128 | 3,179,464 | 1,673,218 | 2,304,750 |
| Jun 2025 | 0 | — | -1,750,515 | -1,733,351 | 5,574,455 | 2,211,575 | 2,514,043 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-7,806,292
Investing CF
$0
Financing CF
$8,738,212
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.22
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-139,719,999
Inventory
—
Receivables
$420,345
ST Investments
—
EBIT TTM
$-10,157,420
Pretax Income TTM
$-10,176,187
Interest Exp TTM
$18,767
Analysts
1
Yahoo Snapshot (yfinance, live)
Total Revenue
$4,707,877
EBITDA
—
Free Cash Flow
$-5,501,255
Enterprise Value
$3,853,062
Total Cash
$745,482
Total Debt
$245,849
Shares Out
14,694,492
Trailing EPS
$-3.25
Book Value
$-0.04
ROE
-1149.1%
ROA
-218.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -10,240,946 | -10,175,700 | 7,452,479 | 4,567,729 | — | -7,806,292 |
| Dec 2024 | 0 | -6,730,134 | -7,986,935 | 5,597,232 | 2,217,293 | — | -7,502,700 |
| Dec 2023 | 0 | -10,718,187 | -10,613,074 | 2,708,085 | 3,359,352 | — | -10,779,982 |
| Dec 2022 | 0 | -24,222,095 | -24,172,292 | 5,885,052 | 9,914,704 | — | -17,887,439 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.23
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| GELS | Gelteq Ltd | $4.52M | $0.42 | — |
| PMHS | Polomar Health Services, Inc. | $4.56M | $0.15 | — |
| MTNB | Matinas BioPharma Holdings, Inc. | $4.66M | $0.73 | — |
| ALZN | Alzamend Neuro, Inc. | $4.38M | $1.15 | — |
| ACUT | Accustem Sciences Inc. | $4.34M | $0.27 | — |
News headlines (Yahoo Finance, 1h cache)
ENSC Advancing Testing and Expanding Potential
2026-05-18 11:04 · Yahoo
Ensysce Biosciences Reports First Quarter 2026 Financial Results
2026-05-15 20:15 · Yahoo
Ensysce Biosciences Announces Expansion of Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology
2026-05-12 12:00 · Yahoo
Ensysce Biosciences CEO Presents at Inaugural Clinical Pain Symposium in Amsterdam
2026-05-08 12:00 · Yahoo
Ensysce Biosciences Secures IRB Approval of Final Phase of PF614-MPAR-102 Clinical Study
2026-04-16 12:00 · Yahoo
Ensysce Biosciences Secures Second Financing From 2025 Agreement to Advance Breakthrough Pain Programs
2026-04-07 12:00 · Yahoo
ENSC Making Great Strides Toward Commercialization
2026-03-31 11:08 · Yahoo
Ensysce Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results
2026-03-30 20:50 · Yahoo
Ensysce Biosciences Initiates Live "Ask Me Anything" (AMA) Session Highlighting Growth and Future Plans
2026-03-04 13:45 · Yahoo
Ensysce Biosciences Announces First Peer-Reviewed Clinical Publication Demonstrating Oral Overdose Protection with MPAR(R) Technology
2026-03-03 13:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.